KREMEN1 and Alzheimer disease: Dysregulation of miR-137 might influence AD pathology by altering the protein levels of its target genes, including CACNA1C (Calcium Voltage-Gated Channel Subunit Alpha1 C), PTN (Pleiotrophin), SPTLC1 (serine palmitoyltransferase long-chain base subunit 1), MAGL (monoacylglycerol lipase), USP30 (Ubiquitin-specific peptidase 30), and KREMEN1 (Kringle-Containing Transmembrane Protein 1) (Table 1), thereby modulating processes such as tau phosphorylation, apoptosis, mitochondrial, neuroinflammation, and the endocannabinoid system [37,44,48,49,50,51].